SCHEMBL21032741

SCHEMBL21032741

Cc1cc(S(=O)(=O)c2cc3cc(Cl)ccc3oc2=O)ccc1F

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 5/20 0.60
KMT2A Q03164 5/20 0.60
ATM Q13315 5/20 0.60
CRHBP P24387 1/20 0.60
CRHR2 Q13324 1/20 0.60
CA12 O43570 1/20 0.56
CA1 P00915 1/20 0.56
CA2 P00918 1/20 0.56
CA9 Q16790 1/20 0.56
RXFP1 Q9HBX9 2/20 0.54
LMNA P02545 4/20 0.53
PKM P14618 4/20 0.53
NPSR1 Q6W5P4 2/20 0.53
KDM4E B2RXH2 4/20 0.50
TP53 P04637 4/20 0.50
SMN1; SMN2 Q16637 3/20 0.50
ALDH1A1 P00352 2/20 0.50
GAA P10253 2/20 0.50
MAPT P10636 1/20 0.50
MAPK1 P28482 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21033632 0.90 ATM (0.62) MEN1KMT2AATMCRHBPCRHR2
SCHEMBL21033389 0.89 MEN1 (0.61) MEN1KMT2AATMCRHBPCRHR2
SCHEMBL21032745 0.87 LMNA (0.72) MEN1KMT2AATMCRHBPCRHR2
SCHEMBL20435641 0.86 CA12 (0.58) MEN1KMT2AATMCA12CA1
SCHEMBL21032740 0.86 RXFP1 (0.76) MEN1KMT2AATMCRHBPCRHR2
SCHEMBL20435613 0.85 KDM4E (0.70) MEN1KMT2AATMCRHBPCRHR2
SCHEMBL20435631 0.85 PKM (0.72) MEN1KMT2AATMCA12CA1
SCHEMBL21033100 0.84 CA12 (0.68) MEN1KMT2AATMCA12CA1
SCHEMBL21033042 0.82 CA12 (0.62) MEN1KMT2AATMCA12CA1
SCHEMBL21033635 0.82 CA12 (0.62) MEN1KMT2AATMCA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11377442-B2 Small molecule agonists and antagonists of NR2F6 activity Zander Biologics, Inc (US) 2022-07-05 US disclosed
US-20200071307-A1 SMALL MOLECULE AGONISTS AND ANTAGONISTS OF NR2F6 ACTIVITY IN ANIMALS Zander Therapeutics, Inc. (US) 2020-03-05 US disclosed
US-10472351-B2 Small molecule agonists and antagonists of NR2F6 activity in animals Zander Therapeutics, Inc. (US) 2019-11-12 US disclosed
WO-2019104199-A1 SMALL MOLECULE AGONISTS AND ANTAGONISTS OF NR2F6 ACTIVITY REGEN BIOPHARMA INC. (US) 2019-05-31 WO disclosed
WO-2019104201-A1 SMALL MOLECULE AGONISTS AND ANTAGONISTS OF NR2F6 ACTIVITY IN NON-HUMANS Zander Therapeutics, Inc. (US) 2019-05-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200071307-A1 SMALL MOLECULE AGONISTS AND ANTAGONISTS OF NR2F6 ACTIVITY IN ANIMALS NR4A2, NR2C2, NR0B2 MEN1 4273/4885KMT2A 904/4885ATM 3281/4885
US-11377442-B2 Small molecule agonists and antagonists of NR2F6 activity NR4A2, NR2C2, NR2F2 MEN1 4260/4885KMT2A 968/4885ATM 3533/4885
US-10472351-B2 Small molecule agonists and antagonists of NR2F6 activity in animals NR4A2, NR2C2, NR0B2 MEN1 4273/4885KMT2A 904/4885ATM 3281/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.